These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 1847867)

  • 21. Fibrinolytic mechanism, biochemistry, and preclinical pharmacology of recombinant prourokinase.
    Credo RB; Burke SE
    J Vasc Interv Radiol; 1995; 6(6 Pt 2 Suppl):8S-18S. PubMed ID: 8770836
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Soluble expression of a strong thrombolytic pro-urokinase mutant in Escherichia coli.
    Lin J; Yang X; Deng R; Yu B; Lai H; Sun W; Wu W
    Protein Expr Purif; 2006 Jul; 48(1):69-73. PubMed ID: 16503165
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Refolding and purification of rhNTA protein by chromatography.
    Fan X; Xu D; Lu B; Xia J; Wei D
    Biomed Chromatogr; 2009 Mar; 23(3):257-66. PubMed ID: 19101913
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Refolding and purification of a urokinase plasminogen activator fragment by chromatography.
    Fahey EM; Chaudhuri JB; Binding P
    J Chromatogr B Biomed Sci Appl; 2000 Jan; 737(1-2):225-35. PubMed ID: 10681059
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Catalytic and fibrinolytic properties of recombinant urokinase plasminogen activator from E. coli, mammalian, and yeast cells.
    Wang P; Zhang J; Sun Z; Chen Y; Gurewich V; Liu JN
    Thromb Res; 2000 Dec; 100(5):461-7. PubMed ID: 11150590
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Purification and characterization of recombinant single-chain urokinase produced in Escherichia coli.
    Winkler ME; Blaber M
    Biochemistry; 1986 Jul; 25(14):4041-5. PubMed ID: 3527262
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Implication of cysteine residues in the activity of single-chain urokinase-plasminogen activator.
    Hamelin J; Sarmientos P; Orsini G; Galibert F
    Biochem Biophys Res Commun; 1993 Jul; 194(2):978-85. PubMed ID: 8343178
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Characterization of a recombinant chimeric plasminogen activator composed of a fibrin fragment-D-dimer-specific humanized monoclonal antibody and a truncated single-chain urokinase.
    Vandamme AM; Dewerchin M; Lijnen HR; Bernar H; Bulens F; Nelles L; Collen D
    Eur J Biochem; 1992 Apr; 205(1):139-46. PubMed ID: 1313361
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Renaturation, purification and characterization of streptokinase expressed as inclusion body in recombinant E. coli.
    Cherish Babu PV; Srinivas VK; Krishna Mohan V; Krishna E
    J Chromatogr B Analyt Technol Biomed Life Sci; 2008 Jan; 861(2):218-26. PubMed ID: 17981102
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Refolding, purification, and activation of miniplasminogen and microplasminogen isolated from E. coli inclusion bodies.
    Medynski D; Tuan M; Liu W; Wu S; Lin X
    Protein Expr Purif; 2007 Apr; 52(2):395-402. PubMed ID: 17126563
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Single-chain urokinase-type plasminogen activator does not possess measurable intrinsic amidolytic or plasminogen activator activities.
    Husain SS
    Biochemistry; 1991 Jun; 30(23):5797-805. PubMed ID: 1828371
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Optimizing the promoter and ribosome binding sequence for expression of human single chain urokinase-like plasminogen activator in Escherichia coli and stabilization of the product by avoiding heat shock response.
    Surek B; Wilhelm M; Hillen W
    Appl Microbiol Biotechnol; 1991 Jan; 34(4):488-94. PubMed ID: 1367523
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Purification and renaturation of recombinant human lymphotoxin (tumour necrosis factor beta) expressed in Escherichia coli as inclusion bodies.
    Jin H; Uddin MS; Huang YL; Teo WK
    J Chem Technol Biotechnol; 1994 Jan; 59(1):67-72. PubMed ID: 7764497
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mutation of Arg154 to Gly154 in urokinase augments its fibrin-specificity.
    Peng G; Ma Z; Kuai L; Zhu D
    Biochem Mol Biol Int; 1997 Apr; 41(5):887-94. PubMed ID: 9137818
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Glucosyldiacylglycerol enhances reciprocal activation of prourokinase and plasminogen.
    Wu W; Narasaki R; Maeda F; Hasumi K
    Biosci Biotechnol Biochem; 2004 Jul; 68(7):1549-56. PubMed ID: 15277760
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Characterization of domain deletion and/or duplication mutants of a recombinant chimera of tissue-type plasminogen activator and urokinase-type plasminogen activator (rt-PA/u-PA).
    Nelles L; Lijnen HR; Van Nuffelen A; Demarsin E; Collen D
    Thromb Haemost; 1990 Aug; 64(1):53-60. PubMed ID: 2148847
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Activation with plasmin of tow-chain urokinase-type plasminogen activator derived from single-chain urokinase-type plasminogen activator by treatment with thrombin.
    Lijnen HR; Van Hoef B; Collen D
    Eur J Biochem; 1987 Dec; 169(2):359-64. PubMed ID: 2961562
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Renaturation of recombinant human pro-urokinase expressed in Escherichia coli.
    Hua ZC; Dong C; Zhu DX
    Biochem Biophys Res Commun; 1996 Mar; 220(1):131-6. PubMed ID: 8602832
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Purification and characterization of single-chain urokinase-type plasminogen activator (pro-urokinase) from human A431 cells.
    Corti A; Nolli ML; Soffientini A; Cassani G
    Thromb Haemost; 1986 Oct; 56(2):219-24. PubMed ID: 3101222
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prolonged half-life in the circulation of a chemical conjugate between a pro-urokinase derivative and human serum albumin.
    Breton J; Pezzi N; Molinari A; Bonomini L; Lansen J; Gonzalez De Buitrago G; Prieto I
    Eur J Biochem; 1995 Aug; 231(3):563-9. PubMed ID: 7649155
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.